BlackRock, Inc. 13D and 13G filings for OncoCyte Corporation:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2022-05-09 3:23 pm Purchase | 2022-04-30 | 13G | OncoCyte Corporation OCX | BlackRock Inc. BLK | 250,261 4.200% | 604 (+0.24%) | Filing |
| 2022-02-04 4:12 pm Purchase | 2021-12-31 | 13G | OncoCyte Corporation OCX | BlackRock Inc. BLK | 249,657 5.400% | 69,906 (+38.89%) | Filing |
| 2021-02-10 3:04 pm Purchase | 2021-01-31 | 13G | OncoCyte Corporation OCX | BlackRock Inc. BLK | 179,752 4.600% | 4,650 (+2.66%) | Filing |
| 2021-02-02 3:13 pm Purchase | 2020-12-31 | 13G | OncoCyte Corporation OCX | BlackRock Inc. BLK | 175,102 5.200% | 175,102 (New Position) | Filing |